Results of a randomised, double-blind, parallel-group study assessing safety and efficacy of 40 mg vs. 20 mg of glatiramer acetate on MRI-measured disease activity in relapsing-remitting multiple sclerosis

被引：0
|
作者：
Rovaris, M.
Cohen, J.
Goodman, A.
Comi, G.
Filippi, M.
机构：
来源：
JOURNAL OF NEUROLOGY | 2006年 / 253卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：144 / 144
页数：1
相关论文
共 50 条
  • [21] Glatiramer acetate 20mg subcutaneous twice-weekly versus daily injections: results of a pilot, prospective, randomised, and rater-blinded clinical and MRI 2-year study in relapsing-remitting multiple sclerosis
    Khan, O.
    Perumal, J.
    Caon, C.
    Tselis, A.
    Latif, Z.
    Ching, W.
    Bao, F.
    Zak, I.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S249 - S250
  • [22] Results from the CLARITY Study: a Phase III, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Oral Cladribine in Relapsing-Remitting Multiple Sclerosis (RRMS)
    Giovannoni, Gavin
    Comi, Giancarlo
    Cook, Stuart D.
    Rammohan, Kottil W.
    Rieckmann, Peter
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Chang, Peter
    Hamlett, Anthony
    Musch, Bruno
    Greenberg, Steven J.
    NEUROLOGY, 2009, 73 (04) : 330 - 330
  • [23] Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
    Comi, G.
    Pulizzi, A.
    Rovaris, M.
    Abramsky, O.
    Arbizu, T.
    Boiko, A.
    Gold, R.
    Havrdova, E.
    Komoly, S.
    Selmaj, K. W.
    Sharrack, B.
    Filippi, M.
    LANCET, 2008, 371 (9630): : 2085 - 2092
  • [24] Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study
    Kuna, P.
    Bachert, C.
    Nowacki, Z.
    van Cauwenberge, P.
    Agache, I.
    Fouquert, L.
    Roger, A.
    Sologuren, A.
    Valiente, R.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2009, 39 (09): : 1338 - 1347
  • [25] A Comparative Placebo-Controlled Clinical Trial of the Efficacy and Safety of Glatiramer Acetate 20 mg in Patients with Remitting Multiple Sclerosis: First-Year Study Results
    Boiko A.N.
    Lashch N.Y.
    Sharanova S.N.
    Zakharova M.N.
    Trifonova O.V.
    Simaniv T.O.
    Lysogorskaya E.V.
    Gur’yanova O.E.
    Kotov S.V.
    Yakushina T.I.
    Lizhdvoi V.Y.
    Belova Y.A.
    Khabirov F.A.
    Babicheva N.N.
    Khaibullin T.I.
    Granatov E.V.
    Aver’yanova L.A.
    Sazonov D.V.
    Odinak M.M.
    Trinitatskii Y.V.
    Tsukurova L.A.
    Sergeeva A.I.
    Ivanov R.A.
    Shustova M.S.
    Neuroscience and Behavioral Physiology, 2018, 48 (3) : 351 - 357
  • [26] Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study
    Comi, G.
    Abramsky, O.
    Arbizu, T.
    Boyko, A.
    Gold, R.
    Havrdova, E.
    Komoly, S.
    Selmaj, K.
    Sharrack, B.
    Filippi, M.
    MULTIPLE SCLEROSIS, 2010, 16 (11): : 1360 - 1366
  • [27] Patient experience with glatiramer acetate 40mg/1ml three-times weekly treatment for relapsing-remitting multiple sclerosis: results from the GLACIER extension study
    Wynn, D.
    Kolodny, S.
    Rubinchick, S.
    Steinerman, J.
    Knappertz, V.
    Wolinsky, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 828 - 828
  • [28] Results of a non-randomised, parallel-group clinical trial to assess efficacy and safety of fingolimod in treatment-naive and previously treated patients with relapsing-remitting multiple sclerosis. The EARLIMS Study
    Montalban, X.
    Fernandez, O.
    Butzkueven, H.
    Barnett, M.
    Nelson, M.
    Garcia, E.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 280 - 281
  • [29] Efficacy and safety of ponesimod compared to teriflunomide in patients with relapsing multiple sclerosis: results of the randomized, active-controlled, double-blind, parallel-group phase 3 OPTIMUM study
    Kappos, L.
    Burcklen, M.
    Freedman, M. S.
    Fox, R.
    Havrdova, E. K.
    Hennessy, B.
    Hohlfeld, R.
    Lublin, F.
    Montalban, X.
    Pozzilli, C.
    Scherz, T.
    Linscheid, P.
    Pirozek-Lawniczek, M.
    Kracker, H.
    Sprenger, T.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 30 - 31
  • [30] Higher medication satisfaction and treatment adherence in relapsing-remitting multiple sclerosis patients treated with glatiramer acetate 40 mg/ml three-times weekly compared with 20 mg/ml daily: 6-month results of the CONFIDENCE study
    Veneziano, A.
    Cutter, G.
    Al-Banna, M.
    Rossi, S.
    Zakharova, M.
    Boyko, A.
    Gandhi, S.
    Everts, R.
    Grinspan, A.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 641 - 642
12345